SecBot SecBot
8-K ·Filed Nov 2, 2026

CRMD

CorMedix Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed14d 19h ago SEC0001213900-26-114665
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The CMS final rule provides a clear Q1 2027 Add-on of $8.32, but the trajectory for Q2-Q4 2027 is uncertain and depends on CMS's quarterly calculation methodology and utilization data. The November 12 earnings call will provide Q3 2026 financials and likely more detail on 2027 Add-on expectations. Monitor for any divergence between management's Add-on projections and actual CMS quarterly adjustments.

DirectionNeutral
Confidencehigh
Horizonweeks

DefenCath

● Neutral Named in this 8-K
Impact
Phase
Not stated
Time to market
Not stated
Next catalyst
None dated

What to watchDefenCath is already approved and generating revenue, so the next major swing factor is the 2027 Medicare pass-through payment rate, which DaVita warned could drop sharply. Watch for CMS rate-setting updates in early 2027 and the company's Q4 2026 earnings call for 2027 guidance on DefenCath specifically. The Heron acquisition diversifies revenue but adds integration risk.

Price Chart

Loading chart...

Executive Summary

CorMedix issued a business update press release reaffirming full-year 2026 revenue guidance of $325M-$345M and reporting unaudited cash of ~$355M as of September 30, 2026. The key event is the CMS 2027 ESRD PPS final rule setting the Q1 2027 DefenCath Add-on at $8.32 per session (3x-5x the current $2.37), with management projecting the average 2027 Add-on will exceed 2x the current rate. No Q3 2026 financial results were released; a full earnings call is scheduled for November 12, 2026.

Key Financial Metrics

Guidance
$325M-$345M
maintained

Key Facts

  • Unaudited cash and cash equivalents as of September 30, 2026: ~$355 million.
  • Full-year 2026 total revenue guidance reaffirmed at $325M-$345M.
  • CMS 2027 ESRD PPS final rule (Oct 28, 2026) set Q1 2027 DefenCath Add-on at $8.32 per dialysis session, within the company's previously guided 3x-5x range above the current $2.37.
  • Management expects the average 2027 Add-on rate to exceed 2x the current $2.37 rate, with quarterly fluctuations (Q2 decline, Q3/Q4 increase).
  • CorMedix distanced itself from third-party projections about future Add-on quarterly adjustments, stating it did not provide utilization or pricing data to any LDO.
  • Full Q3 2026 earnings call scheduled for November 12, 2026.

Financial Impact

Cash position of ~$355M; 2026 revenue guidance $325M-$345M; Q1 2027 DefenCath Add-on of $8.32/session vs current $2.37/session, with management projecting average 2027 Add-on >2x current rate.

revenuecashreimbursement rate

Risk Factors

  • The 2027 Add-on rate is subject to quarterly adjustments by CMS based on utilization data; actual rates may differ materially from management's estimates.
  • Increased reimbursement to dialysis facilities may not translate into corresponding increases in CorMedix's realized pricing, product utilization, or revenue.
  • Third-party projections about future Add-on adjustments create uncertainty; the company has not endorsed any such projections.
  • Continued pricing pressures and actions by governmental and private payers could affect DefenCath reimbursement and utilization.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-114665
Document: ea031044501ex99-1.htm0001213900-26-114665
Document: 0001213900-26-114665-index-headers.html0001213900-26-114665
Document: 0001213900-26-114665-index.html0001213900-26-114665
Document: 0001213900-26-114665.txt0001213900-26-114665
8-K Data (Synthetic)0001213900-26-114665

Track record

21 reports on CRMD

Performance horizon

9 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 10 of 12 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
  2. Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
  3. Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
  4. Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
  5. Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
  6. Nov 2, 202614d ago 8-K Neutral 5/10 Viewing No price data
  7. Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
  8. Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
  9. Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
  10. Aug 13, 202613w ago 8-K Neutral 5/10 No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026